Compare HASI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HASI | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | 2012 | 2020 |
| Metric | HASI | LEGN |
|---|---|---|
| Price | $40.79 | $29.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $44.38 | ★ $61.33 |
| AVG Volume (30 Days) | 899.8K | ★ 2.9M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $400,502,000.00 | N/A |
| Revenue This Year | $79.17 | $42.68 |
| Revenue Next Year | $207.88 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $24.29 | $16.24 |
| 52 Week High | $44.13 | $45.30 |
| Indicator | HASI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 67.46 |
| Support Level | $40.21 | $21.27 |
| Resistance Level | N/A | $29.69 |
| Average True Range (ATR) | 1.30 | 2.04 |
| MACD | -0.29 | 0.21 |
| Stochastic Oscillator | 20.48 | 83.77 |
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.